Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of genetically engineered bacterium VNP20009-M to preparation of lung cancer prevention and treatment drugs

A VNP20009-M, a technology of genetically engineered bacteria, applied in gene therapy, microorganism-based methods, drug combinations, etc., can solve problems such as no observed anti-tumor effect

Pending Publication Date: 2017-07-04
GUANGZHOU SINOGEN PHARMA CO LTD
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Two phase I clinical studies conducted in the United States have shown that it can be used in humans and is safe, but no anti-tumor effects have been observed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of genetically engineered bacterium VNP20009-M to preparation of lung cancer prevention and treatment drugs
  • Application of genetically engineered bacterium VNP20009-M to preparation of lung cancer prevention and treatment drugs
  • Application of genetically engineered bacterium VNP20009-M to preparation of lung cancer prevention and treatment drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] The construction of embodiment 1 genetically engineered bacteria VNP20009-M

[0040] The construction method and process of the genetically engineered bacteria VNP20009-M of the present invention are as described in the examples of Chinese patent CN105983103A.

[0041] (1) Construction of a plasmid expressing the L-methioninase gene.

[0042]Synthesized L-methioninase (GenBank: L43133.1) gene was subcloned into pUC57 plasmid (GenScript), and then subcloned into pSVSPORT plasmid (invitrogen) through Kpn I and Hind III restriction sites to obtain pSVSPORT-L- methioninase expression plasmid. The specific construction process is as follows:

[0043] Digest the pSVSPORT plasmid with Kpn I and Hind III. The digestion system is: 2 μg plasmid DNA, 3 μL 10×buffer, 1.5 μL Kpn I enzyme, 1.5 μL Hind III enzyme, add ddH2O to make up the volume to 30 μL, and incubate at 37°C for 3 hours . Then the digestion system was separated by electrophoresis in 1% agarose gel, the DNA band w...

Embodiment 2

[0054] The antitumor effect of embodiment 2 genetically engineered bacteria VNP20009-M

[0055] 1), past medical history and diagnosis

[0056] A male patient, 73 years old, underwent thoracoscopic radical resection of squamous cell carcinoma of the lower lobe of the right lung 5 months after a new mass was found in the neck (such as Figure 4 As shown), the size of the lesion at the neck was measured to be about 8cm×9cm. Biopsy of the mass site identified as cancerous by cell smear (eg, Figure 5 shown), and skeletal ECT showed active bone metabolism in multiple places, and chest CT examination reported sternal destruction with mass formation.

[0057] According to the patient's previous treatment and related examinations, the patient was diagnosed with recurrence and metastasis of right lower lobe squamous cell carcinoma after surgery, but there is no standard clinical treatment plan.

[0058] 2) Treatment plan

[0059] The diluted VNP20009-M was evenly injected into the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of genetically engineered drugs, and particularly relates to novel application of the genetically engineered bacterium VNP20009-M to preparation of lung cancer prevention and treatment drugs. The genetically engineered bacterium VNP20009-M is applied to lung cancer treatment on the present basis, and the genetically engineered bacterium VNP20009-M can effectively kill tumor cells and eliminate tumor lesions; furthermore, the genetically engineered bacterium has no obvious toxic or side effect on the human body, and a safe and effective novel approach is provided for lung cancer treatment.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering drugs, and in particular relates to a new application of genetic engineering bacteria VNP20009-M in the preparation of drugs for preventing and treating lung cancer. Background technique [0002] Cancer has become an important cause of human death, and the incidence of cancer increased by 33% between 2005 and 2015. The "Global Cancer Report 2014" published by the World Health Organization (WHO) predicts that global cancer cases will show a rapid growth trend, from 14 million in 2012 to 19 million in 2025, and will reach 24 million in 2035 . [0003] Among them, lung cancer is one of the most threatening malignant tumors to the health and life of the population, and its morbidity and mortality both rank first. In 2012 alone, almost 1.6 million people died of lung cancer worldwide. According to the 2015 annual report of the China Cancer Registry Center, the morbidity and mortality of l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K38/51A61K35/74A61P35/00A61P35/04
CPCA61K38/51A61K48/005A61K35/74A61K2300/00Y02A50/30A61P35/00A61P11/00A61K9/0019C12N15/74C12N1/205C12R2001/42
Inventor 赵子建林艳周素瑾李芳红
Owner GUANGZHOU SINOGEN PHARMA CO LTD